(19)
(11) EP 0 914 102 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.11.2005 Bulletin 2005/44

(45) Mention of the grant of the patent:
24.08.2005 Bulletin 2005/34

(21) Application number: 97921563.9

(22) Date of filing: 26.05.1997
(51) International Patent Classification (IPC)7: A61K 31/00, A61K 31/28, A61K 31/335
(86) International application number:
PCT/CA1997/000345
(87) International publication number:
WO 1997/045105 (04.12.1997 Gazette 1997/52)

(54)

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES OF BODY PASSAGEWAYS

ZUBEREITUNGEN UND VERFAHREN ZUR BEHANDLUNG ODER PRÄVENTION VON KRANKHEITEN DER KÖRPERPASSAGEWEGE

COMPOSITIONS ET METHODES POUR TRAITER OU PREVENIR DES MALADIES DES VOIES CORPORELLES

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 24.05.1996 US 653207

(43) Date of publication of application:
12.05.1999 Bulletin 1999/19

(60) Divisional application:
05018291.4

(73) Proprietors:
  • Angiotech Pharmaceuticals, Inc.
    Vancouver, British Columbia V6A 1B6 (CA)
  • THE UNIVERSITY OF BRITISH COLUMBIA
    Vancouver, British Columbia V6T 1Z3 (CA)

(72) Inventors:
  • HUNTER, William, L.
    Vancouver, British Columbia V6A 1B6 (CA)
  • MACHAN, Lindsay, S.
    Vancouver, British Columbia V6R 1A1 (CA)

(74) Representative: Gowshall, Jonathan Vallance 
FORRESTER & BOEHMERT Pettenkoferstrasse 20-22
80336 München
80336 München (DE)


(56) References cited: : 
WO-A-92/15282
WO-A-95/03036
 WO-A-93/19739
US-A- 3 797 485
   
  • DATABASE WPI Section Ch, Week 9541 Derwent Publications Ltd., London, GB; Class B05, AN 95-311860 XP002043084 & CA 2 113 683 A (MOUNT SINAI HOSPITAL CORP) , 19 July 1995
  • K.HARADA ET AL.: "Basic fibroplast growth factor improves myocardial function in chronically ischemic porcine hearts" J.CLIN.INVEST., vol. 94, no. 2, 1994, pages 623-630, XP002043081
  • AUGUSTO E. VILLA ET AL.: "Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty" J.CLIN.INVEST., vol. 93, no. 3, 1994, pages 1243-1249, XP002043082
  • REIMER RIESSEN ET AL.: "Prospects for site-specific delivery of pharmacologic and molecular therapies" J.AM.COLL.CARDIOL., vol. 23, no. 5, 1994, pages 1234-1244, XP002043083
  • LOVICH M.A. ET AL CIRCULATION RESEARCH vol. 77, no. 6, 1995, pages 1143 - 1149
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).